Biogen | BIIB - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 41.64B 458M 2026-06
Acadia Pharmaceuticals USD 361.44M 55.91M 2026-06
ALKERMES USD 662.09M 62.59M 2026-06
Amgen USD 25.5B 547M 2026-06
Bayer EUR 32.27B 1.19B 2026-06
Biogen USD 3.9B 18.7M 2026-09
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Bristol-Myers Squibb USD 18.75B 94M 2026-09
Eli Lilly USD 47B 745M 2026-09
Gilead Sciences USD 12B 982M 2026-09
Incyte USD 1.44B 125.72M 2026-09
Merck USD 27.73B 786M 2026-06
Moderna USD 2.53B 139M 2026-06
Neurocrine Biosciences USD 874.5M 42.8M 2026-06
Novartis USD 31.75B 374M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
PTC Therapeutics USD 776.08M 5.01M 2026-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 31.93B 1.92B 2026-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Teva Pharmaceutical Industries USD 15.65B 2.11B 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
United Therapeutics USD 607.8M 8.7M 2026-06
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06